BACKGROUND: Most BRCA1 or BRCA2 mutation carriers have inherited a single (heterozygous) mutation. Transheterozygotes (TH) who have inherited deleterious mutations in both BRCA1 and BRCA2 are rare, and the consequences of transheterozygosity are poorly understood. METHODS: From 32,295 female BRCA1/2 mutation carriers, we identified 93 TH (0.3 %). "Cases" were defined as TH, and "controls" were single mutations at BRCA1 (SH1) or BRCA2 (SH2). Matched SH1 "controls" carried a BRCA1 mutation found in the TH "case". Matched SH2 "controls" carried a BRCA2 mutation found in the TH "case". After matching the TH carriers with SH1 or SH2, 91 TH were matched to 9316 SH1, and 89 TH were matched to 3370 SH2. RESULTS: The majority of TH (45.2 %) involved the three common Jewish mutations. TH were more likely than SH1 and SH2 women to have been ever diagnosed with breast cancer (BC; p = 0.002). TH were more likely to be diagnosed with ovarian cancer (OC) than SH2 (p = 0.017), but not SH1. Age at BC diagnosis was the same in TH vs. SH1 (p = 0.231), but was on average 4.5 years younger in TH than in SH2 (p < 0.001). BC in TH was more likely to be estrogen receptor (ER) positive (p = 0.010) or progesterone receptor (PR) positive (p = 0.013) than in SH1, but less likely to be ER positive (p < 0.001) or PR positive (p = 0.012) than SH2. Among 15 tumors from TH patients, there was no clear pattern of loss of heterozygosity (LOH) for BRCA1 or BRCA2 in either BC or OC. CONCLUSIONS: Our observations suggest that clinical TH phenotypes resemble SH1. However, TH breast tumor marker characteristics are phenotypically intermediate to SH1 and SH2.

4301 West Markham Street Slot 793 Little Rock AR 72205 USA

513 Parnassus Ave HSE 901E San Francisco CA 94143 0794 USA

5841 South Maryland Avenue MC 2115 Chicago IL USA

Biomedical Network on Rare Diseases Madrid Spain

Biostatistics Unit Group Health Research Institute Seattle WA USA

Cancer Genetics Laboratory Department of Genetics University of Pretoria Private Bag X323 Arcadia 0007 South Africa

Cancer Research Initiatives Foundation Sime Darby Medical Centre 1 Jalan SS12 1A Subang Jaya 47500 Malaysia

Center for Genomic Medicine Rigshospitalet Copenhagen University Hospital Blegdamsvej 9 DK 2100 Copenhagen Denmark

Center for Hereditary Breast and Ovarian Cancer Center for Integrated Oncology Medical Faculty University of Cologne and University Hospital Cologne Cologne Germany

Center for Medical Genetics Ghent University De Pintelaan 185 9000 Gent Belgium

Centre for Cancer Genetic Epidemiology Department of Public Health and Primary Care University of Cambridge Cambridge UK

Centre for Cancer Genetic Epidemiology Department of Public Health and Primary Care University of Cambridge Strangeways Research Laboratory Worts Causeway Cambridge UK

Centre François Baclesse 3 avenue Général Harris Caen France

Clinical Cancer Genetics City of Hope 1500 East Duarte Road Duarte California 91010 USA

Clinical Cancer Genetics Laboratory Memorial Sloane Kettering Cancer Center New York NY USA

Clinical Genetics Branch DCEG NCI NIH 9609 Medical Center Drive Room 6E 454 Bethesda MD USA

Clinical Genetics Research Laboratory Department of Medicine Cancer Biology and Genetics Memorial Sloan Kettering Cancer Center 1275 York Avenue New York NY 10044 USA

Department Epidemiology Dana Farber Cancer Institute and Harvard T H Chan School of Public Health 1101 Dana Building 450 Brookline Avenue Boston MA USA

Department of Biostatistics and Epidemiology Perelman School of Medicine at the University of Pennsylvania Philadelphia PA USA

Department of Breast Medical Oncology and Clinical Cancer Genetics Program University Of Texas MD Anderson Cancer Center 1515 Pressler Street CBP 5 Houston TX USA

Department of Cancer Epidemiology and Genetics Masaryk Memorial Cancer Institute Zluty kopec 7 Brno 65653 Czech Republic

Department of Clinical Genetics Odense University Hospital Sonder Boulevard 29 Odense C Denmark

Department of Epidemiology Cancer Prevention Institute of California 2201 Walnut Avenue Suite 300 Fremont CA 94538 USA

Department of Epidemiology Columbia University New York NY USA

Department of Epidemiology Netherlands Cancer Institute P O Box 90203 1000 BE Amsterdam The Netherlands

Department of Genetics and Computational Biology QIMR Berghofer Institute of Medical Research Brisbane Australia

Department of Genetics and Pathology Pomeranian Medical University Polabska 4 Szczecin Poland

Department of Genetics Portuguese Oncology Institute Rua Dr António Bernardino de Almeida 4200 072 Porto Portugal

Department of Gynaecology and Obstetrics University Hospital Düsseldorf Heinrich Heine University Düsseldorf Düsseldorf Germany

Department of Gynaecology and Obstetrics University Hospital of Schleswig Holstein Campus Kiel Christian Albrechts University Kiel Germany

Department of Gynaecology and Obstetrics University Hospital Ulm Ulm Germany

Department of Health Sciences Research Mayo Clinic 13400 E Scottsdale Blvd Scottsdale AZ USA

Department of Laboratory Medicine and Pathology and Health Sciences Research Mayo Clinic 200 1st Street SW Rochester Minnesota USA

Department of Medical Oncology Beth Israel Deaconess Medical Center 330 Brookline Avenue Boston MA 02215 USA

Department of Medical Oncology Family Cancer Clinic Erasmus University Medical Center Cancer institute P O Box 5201 3008 AE Rotterdam The Netherlands

Department of Medicine Abramson Cancer Center Perelman School of Medicine at the University of Pennsylvania Philadelphia PA USA

Department of Medicine Huntsman Cancer Institute 2000 Circle of Hope Salt Lake City UT 84112 USA

Department of Molecular and Regenerative Medicine Vilnius University Hospital Santariskiu Clinics Hematology oncology and transfusion medicine center Santariskiu st Vilnius Lithuania

Department of Molecular Genetics National Institute of Oncology Budapest Hungary

Department of OB GYN and Comprehensive Cancer Center Medical University of Vienna Waehringer Guertel 18 20 A 1090 Vienna Austria

Department of OB GYN Medical University of Vienna Waehringer Guertel 18 20 A 1090 Vienna Austria

Department of Obstetrics and Gynecology University of Helsinki and Helsinki University Hospital Biomedicum Helsinki P O BOX 700 00029 HUS Helsinki Finland

Department of Oncology Clinical Sciences Lund University and Skåne University Hospital Lund Sweden

Department of Oncology Lund University Hospital Lund Sweden

Department of Pathology and Laboratory Medicine 3901 Rainbow Boulevard 4019 Wahl Hall East MS 3040 Kansas USA

Department of Population Sciences Beckman Research Institute of City of Hope Duarte CA USA

Department of Preventive Medicine Keck School of Medicine USC Norris Comprehensive Cancer Center University of Southern California California USA

Department of Preventive Medicine Seoul National University College of Medicine 103 Daehak ro Jongno gu Seoul 110 799 Korea

Department of Surgery The University of Hong Kong Hong Kong Hong Kong

Departments of Molecular Genetics and Laboratory Medicine and Pathobiology University of Toronto Toronto Ontario Canada

Division of Population Science Fox Chase Cancer Center 333 Cottman Avenue Philadelphia PA 19111 USA

Divison of Human Cancer Genetics Departments of Internal Medicine and Molecular Virology Immunology and Medical Genetics Comprehensive Cancer Center The Ohio State University 998 Biomedical Research Tower Columbus OH USA

Familial Cancer Centre Peter MacCallum Cancer Centre Locked Bag 1 A'Beckett Street Melbourne VIC 8006 Australia

Genetic Epidemiology Laboratory Department of Pathology University of Melbourne Parkville Victoria Australia

Genomic Medicine Manchester Academic Health Sciences Centre Institute of Human Development Manchester University Central Manchester University Hospitals NHS Foundation Trust Manchester UK

Genomics Center Centre Hospitalier Universitaire de Québec Research Center and Laval University 2705 Laurier Boulevard Quebec City Quebec Canada

Gynaecological Oncology The University of Sydney Cancer Centre Royal Prince Alfred Hospital Sydney Australia

Human Genetics Group Spanish National Cancer Centre Madrid Spain

Human Genotyping Madrid Spain

Immunology and Molecular Oncology Unit Veneto Institute of Oncology IOC IRCCS Via Gattamelata 64 Padua Italy

Institute of Oncology Rivka Ziv Medical Center 13000 Zefat Israel

Kathleen Cuningham Consortium for Research into Familial Breast Cancer Peter MacCallum Cancer Center Melbourne Australia

Latvian Biomedical Research and Study Centre Ratsupites str 1 Riga Latvia

Lombardi Comprehensive Cancer Center Georgetown University 3800 Reservoir Road NW Washington DC USA

Lunenfeld Tanenbaum Research Institute Mount Sinai Hospital Toronto Ontario M5G 1X5 Canada

Molecular Diagnostic Unit Hereditary Cancer Program IDIBELL Catalan Institute of Oncology Gran Via de l'Hospitalet 199 203 08908 L'Hospitalet Barcelona Barcelona Spain

Molecular Diagnostics Laboratory Institute of Nuclear and Radiological Sciences and Technology National Centre for Scientific Research Demokritos Patriarchou Gregoriou and Neapoleos str Aghia Paraskevi Attikis Athens Greece

Molecular Genetics of Breast Cancer German Cancer Research Center Im Neuenheimer Feld 580 69120 Heidelberg Germany

Molecular Oncology Laboratory Hospital Clinico San Carlos IdISSC Martin Lagos s n Madrid Spain

N N Petrov Institute of Oncology St Petersburg 197758 Russia

National Human Genome Research Institute National Institutes of Health Building 50 Room 5312 50 South Drive MSC 004 Bethesda MD 20892 8004 USA

NRG Oncology Statistics and Data Management Center Roswell Park Cancer Institute Elm St and Carlton St Buffalo NY 14263 USA

Oncogenetics Group Vall d'Hebron Institute of Oncology Clinical and Molecular Genetics Area Vall d'Hebron University Hospital Passeig Vall d'Hebron 119 129 Barcelona Spain

Ontario Cancer Genetics Network Samuel Lunenfeld Research Institute Mount Sinai Hospital Toronto Ontario M5G 1X5 Canada

Present Address School of Women's and Children's Health University of New South Wales and The Kinghorn Cancer Centre Garvan Institute of Medical Research 384 Victoria Street Darlinghurst NSW 2010 Australia

Program in Cancer Genetics Departments of Human Genetics and Oncology McGill University Montreal Quebec Canada

Sackler Faculty of Medicine Tel Aviv University Ramat Aviv 69978 Israel

Section of Genetic Oncology Department of Laboratory Medicine University and University Hospital of Pisa Pisa Italy

Service de Génétique Oncologique Institut Curie 26 rue d'Ulm Paris Cedex 05 France

Sir Peter MacCallum Department of Oncology University of Melbourne Parkville VIC 3052 Australia

State Research Institute Centre for Innovative medicine Zygymantu st 9 Vilnius Lithuania

The Faculty of Medicine Bar Ilan University Zefat Israel

The Hong Kong Hereditary Breast Cancer Family Registry; Cancer Genetics Center Hong Kong Sanatorium and Hospital Hong Kong Hong Kong

The Institute of Oncology Chaim Sheba Medical Center Ramat Gan 52621 Israel

The Susanne Levy Gertner Oncogenetics Unit Institute of Human Genetics Chaim Sheba Medical Center Ramat Gan 52621 Israel

UCLA Schools of Medicine and Public Health Division of Cancer Prevention and Control Research Jonsson Comprehensive Cancer Center 650 Charles Young Drive South Room A2 125 HS Los Angeles CA 90095 6900 USA

Unit of Medical Genetics Department of Preventive and Predictive Medicine Fondazione IRCCS Via Giacomo Venezian 1 20133 Milan Italy

Unit of Molecular Bases of Genetic Risk and Genetic Testing Department of Preventive and Predicted Medicine Fondazione IRCCS c o Amaedeolab via GA Amadeo 42 20133 Milan Italy

Unité de Prévention et d'Epidémiologie Génétique Centre Léon Bérard 28 rue Laënnec Lyon France

Unité de recherche en santé des populations Centre des maladies du sein Deschênes Fabia Hôpital du Saint Sacrement 1050 chemin Sainte Foy Québec Canada

University Malaya Cancer Research Institute University Malaya 50603 Kuala Lumpur Malaysia

University of Kansas Medical Center Kansas City Kansas USA

Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute Cedars Sinai Medical Center 8700 Beverly Boulevard Suite 290W Los Angeles CA USA

Zobrazit více v PubMed

Bell DW, Erban J, Sgroi DC, Haber DA. Selective loss of heterozygosity in multiple breast cancers from a carrier of mutations in both BRCA1 and BRCA2. Cancer Res. 2002;62(10):2741–3. PubMed

Birgisdottir V, Stefansson OA, Bodvarsdottir SK, Hilmarsdottir H, Jonasson JG, Eyfjord JE. Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer. Breast Cancer Res. 2006;8(4):R38. doi: 10.1186/bcr1522. PubMed DOI PMC

Canzian F, Salovaara R, Hemminki A, Kristo P, Chadwick RB, Aaltonen LA, de la Chapelle A. Semiautomated assessment of loss of heterozygosity and replication error in tumors. Cancer Res. 1996;56(14):3331–7. PubMed

Chenevix-Trench G, Healey S, Lakhani S, Waring P, Cummings M, Brinkworth R, Deffenbaugh AM, Burbidge LA, Pruss D, Judkins T, et al. Genetic and histopathologic evaluation of BRCA1 and BRCA2 DNA sequence variants of unknown clinical significance. Cancer Res. 2006;66(4):2019–27. doi: 10.1158/0008-5472.CAN-05-3546. PubMed DOI

Chenevix-Trench G, Milne RL, Antoniou AC, Couch FJ, Easton DF, Goldgar DE. An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA). Breast Cancer Res. 2007a;9(2):104 PubMed PMC

Collins N, McManus R, Wooster R, Mangion J, Seal S, Lakhani SR, Ormiston W, Daly PA, Ford D, Easton DF. Consistent loss of the wild type allele in breast cancers from a family linked to the BRCA2 gene on chromosome 13q12-13. Oncogene. 1995;10(8):1673–5. PubMed

Cornelis RS, Neuhausen SL, Johansson O, Arason A, Kelsell D, Ponder BA, Tonin P, Hamann U, Lindblom A, Lalle P. High allele loss rates at 17q12-q21 in breast and ovarian tumors from BRCAl-linked families. The Breast Cancer Linkage Consortium. Genes Chromosomes Cancer. 1995;13(3):203–10. doi: 10.1002/gcc.2870130310. PubMed DOI

Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, Garber JE, Neuhausen SL, Matloff E, Eeles R, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010;304(9):967–75. doi: 10.1001/jama.2010.1237. PubMed DOI PMC

Domchek SM, Tang JB, Stopfer J, Lilli DR, Hamel N, Tischkowitz M, Monteiro AN, Messick TE, Powers J, Yonker A, et al. Biallelic Deleterious BRCA1 mutations in a woman with early-onset ovarian cancer. Cancer Discov. 2013;3(4):399–405. PubMed PMC

Dworkin AM, Spearman AD, Tseng SY, Sweet K, Toland AE. Methylation not a frequent “second hit” in tumors with germline BRCA mutations. Fam Cancer. 2009;8(4):339–46. doi: 10.1007/s10689-009-9240-1. PubMed DOI

Friedman E, Bar-Sade Bruchim R, Kruglikova A, Risel S, Levy-Lahad E, Halle D, Bar-On E, Gershoni-Baruch R, Dagan E, Kepten I, et al. Double heterozygotes for the Ashkenazi founder mutations in BRCA1 and BRCA2 genes. Am J Hum Genet. 1998;63(4):1224–7. doi: 10.1086/302040. PubMed DOI PMC

Goldgar DE, Easton DF, Deffenbaugh AM, Monteiro AN, Tavtigian SV, Couch FJ. Integrated evaluation of DNA sequence variants of unknown clinical significance: application to BRCA1 and BRCA2. Am J Hum Genet. 2004;75(4):535–44. doi: 10.1086/424388. PubMed DOI PMC

Gudmundsson J, Johannesdottir G, Bergthorsson JT, Arason A, Ingvarsson S, Egilsson V, Barkardottir RB. Different tumor types from BRCA2 carriers show wild-type chromosome deletions on 13q12-q13. Cancer Res. 1995;55(21):4830–2. PubMed

Heidemann S, Fischer C, Engel C, Fischer B, Harder L, Schlegelberger B, Niederacher D, Goecke TO, Doelken SC, Dikow N, et al. Double heterozygosity for mutations in BRCA1 and BRCA2 in German breast cancer patients: implications on test strategies and clinical management. Breast Cancer Res Treat. 2012;134(3):1229–39. doi: 10.1007/s10549-012-2050-4. PubMed DOI

Howlett NG, Taniguchi T, Olson S, Cox B, Waisfisz Q, De Die-Smulders C, Persky N, Grompe M, Joenje H, Pals G, et al. Biallelic inactivation of BRCA2 in Fanconi anemia. Science. 2002;297(5581):606–9. doi: 10.1126/science.1073834. PubMed DOI

Khalique L, Ayhan A, Weale ME, Jacobs IJ, Ramus SJ, Gayther SA. Genetic intra-tumour heterogeneity in epithelial ovarian cancer and its implications for molecular diagnosis of tumours. J Pathol. 2007;211(3):286–95. doi: 10.1002/path.2112. PubMed DOI

Khoo US, Chan KY, Cheung AN, Xue WC, Shen DH, Fung KY, Ngan HY, Choy KW, Pang CP, Poon CS, et al. Recurrent BRCA1 and BRCA2 germline mutations in ovarian cancer: a founder mutation of BRCA1 identified in the Chinese population. Hum Mutat. 2002;19(3):307–8. doi: 10.1002/humu.9015. PubMed DOI

King MC, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 2003;302(5645):643–6. doi: 10.1126/science.1088759. PubMed DOI

King TA, Li W, Brogi E, Yee CJ, Gemignani ML, Olvera N, Levine DA, Norton L, Robson ME, Offit K, et al. Heterogenic loss of the wild-type BRCA allele in human breast tumorigenesis. Ann Surg Oncol. 2007;14(9):2510–8. doi: 10.1245/s10434-007-9372-1. PubMed DOI

Lavie O, Narod S, Lejbkowicz F, Dishon S, Goldberg Y, Gemer O, Rennert G. Double heterozygosity in the BRCA1 and BRCA2 genes in the Jewish population. Ann Oncol. 2011;22(4):964–6. doi: 10.1093/annonc/mdq460. PubMed DOI PMC

Liede A, Rehal P, Vesprini D, Jack E, Abrahamson J, Narod SA. A breast cancer patient of Scottish descent with germ-line mutations in BRCA1 and BRCA2. Am J Hum Genet. 1998;62(6):1543–4. doi: 10.1086/301889. PubMed DOI PMC

Mathew CG. Fanconi anaemia genes and susceptibility to cancer. Oncogene. 2006;25(43):5875–84. doi: 10.1038/sj.onc.1209878. PubMed DOI

Merajver SD, Frank TS, Xu J, Pham TM, Calzone KA, Bennett-Baker P, Chamberlain J, Boyd J, Garber JE, Collins FS. Germline BRCA1 mutations and loss of the wild-type allele in tumors from families with early onset breast and ovarian cancer. Clin Cancer Res. 1995;1(5):539–44. PubMed

Meric-Bernstam F. Heterogenic loss of BRCA in breast cancer: the “two-hit” hypothesis takes a hit. Ann Surg Oncol. 2007;14(9):2428–9. doi: 10.1245/s10434-007-9379-7. PubMed DOI

Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994;266(5182):66–71. doi: 10.1126/science.7545954. PubMed DOI

Miolo G, Puppa LD, Santarosa M, De Giacomi C, Veronesi A, Bidoli E, Tibiletti MG, Viel A, Dolcetti R. Phenotypic features and genetic characterization of male breast cancer families: identification of two recurrent BRCA2 mutations in north-east of Italy. BMC Cancer. 2006;6:156. doi: 10.1186/1471-2407-6-156. PubMed DOI PMC

Ramus SJ, Friedman LS, Gayther SA, Ponder BA, Bobrow L, van der Looji M, Papp J, Olah E. A breast/ovarian cancer patient with germline mutations in both BRCA1 and BRCA2. Nat Genet. 1997;15(1):14–5. doi: 10.1038/ng0197-14. PubMed DOI

Randall TC, Bell KA, Rebane BA, Rubin SC, Boyd J. Germline mutations of the BRCA1 and BRCA2 genes in a breast and ovarian cancer patient. Gynecol Oncol. 1998;70(3):432–4. doi: 10.1006/gyno.1998.5081. PubMed DOI

Saslow D, Boetes C, Burke W, Harms S, Leach MO, Lehman CD, Morris E, Pisano E, Schnall M, Sener S, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin. 2007;57(2):75–89. doi: 10.3322/canjclin.57.2.75. PubMed DOI

Sawyer SL, Tian L, Kähkönen M, Schwartzentruber J, Kircher M, Majewski J, Dyment DA, Innes AM, Boycott KM, Moreau LA, et al. Biallelic mutations in BRCA1 cause a new Fanconi anemia subtype. Cancer Discov. 2015;5(2):135–42. doi: 10.1158/2159-8290.CD-14-1156. PubMed DOI PMC

Smith SA, Easton DF, Evans DG, Ponder BA. Allele losses in the region 17q12-21 in familial breast and ovarian cancer involve the wild-type chromosome. Nat Genet. 1992;2(2):128–31. doi: 10.1038/ng1092-128. PubMed DOI

Soegaard M, Kjaer SK, Cox M, Wozniak E, Høgdall E, Høgdall C, Blaakaer J, Jacobs IJ, Gayther SA, Ramus SJ. BRCA1 and BRCA2 mutation prevalence and clinical characteristics of a population-based series of ovarian cancer cases from Denmark. Clin Cancer Res. 2008;14(12):3761–7. doi: 10.1158/1078-0432.CCR-07-4806. PubMed DOI

Suijkerbuijk KP, Fackler MJ, Sukumar S, van Gils CH, van Laar T, van der Wall E, Vooijs M, van Diest PJ. Methylation is less abundant in BRCA1-associated compared with sporadic breast cancer. Ann Oncol. 2008;19(11):1870–4. doi: 10.1093/annonc/mdn409. PubMed DOI PMC

Tapia T, Smalley SV, Kohen P, Muñoz A, Solis LM, Corvalan A, Faundez P, Devoto L, Camus M, Alvarez M, et al. Promoter hypermethylation of BRCA1 correlates with absence of expression in hereditary breast cancer tumors. Epigenetics. 2008;3(3):157–63. doi: 10.4161/epi.3.3.6387. PubMed DOI

Tesoriero A, Andersen C, Southey M, Somers G, McKay M, Armes J, McCredie M, Giles G, Hopper JL, Venter D. De novo BRCA1 mutation in a patient with breast cancer and an inherited BRCA2 mutation. Am J Hum Genet. 1999;65(2):567–9. doi: 10.1086/302503. PubMed DOI PMC

Tsongalis GJ, Linfert DR, Johnson RC, Ackroyd R, Berman MM, Ricci A. Double heterozygosity for mutations in the BRCA1 and BRCA2 genes in a breast cancer patient. Arch Pathol Lab Med. 1998;122(6):548–50. PubMed

Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 2010;376(9737):235–44. doi: 10.1016/S0140-6736(10)60892-6. PubMed DOI

Wooster R, Neuhausen SL, Mangion J, Quirk Y, Ford D, Collins N, Nguyen K, Seal S, Tran T, Averill D. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science. 1994;265(5181):2088–90. doi: 10.1126/science.8091231. PubMed DOI

Zuradelli M, Peissel B, Manoukian S, Zaffaroni D, Barile M, Pensotti V, Cavallari U, Masci G, Mariette F, Benski AC, et al. Four new cases of double heterozygosity for BRCA1 and BRCA2 gene mutations: clinical, pathological, and family characteristics. Breast Cancer Res Treat. 2010;124(1):251–8. doi: 10.1007/s10549-010-0853-8. PubMed DOI

Early-Onset Ovarian Cancer <30 Years: What Do We Know about Its Genetic Predisposition?

Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations